Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Knowing when to switch from aggressive to conservative investing is key. Understand the signs that indicate it's time to adjust your strategy.
14,591 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Citigroup and Wells Fargo chart different paths: one leans global and institutional, the other domestic and consumer-...
As the Fed considers stricter rules for stablecoins, Circle’s USDC stands to gain in trust and adoption. This deep-di...
A 927-page financial disclosure reveals a modern, automated approach to wealth management, using direct indexing and ...
What would Steve Jobs Do in today’s markets for investors? A fresh, original look at leadership, product focus, and t...
As the financial world evolves, investors must choose between broad sector exposure and a regional bank niche. This g...
From a tiny boat-insurer niche to a public company, Hagerty’s story is a case study in branding, community, and strat...
Bill Ackman's closed-end fund recently trades at a sizable discount, prompting questions about a Berkshire-style bet....
When healthcare stocks rally, two ETFs often surface as popular bets: Vanguard Health Care (VHT) and Invesco Pharmace...
Roundhill unveiled plans for a suite of ETFs that would track prediction-market odds on the 2028 U.S. election, signa...
Insider moves can tell us a lot about a stock’s near-term path. When Intuitive Machines’ CEO disclosed a $1.39 millio...
Six non-AI chip makers could be poised to benefit from the AI boom, as demand broadens beyond headline AI chips. Here...